Objectives: The purpose of the study is to determine the level of serum uric acid (s. uric acid) above which all complications occur, to analyze the maternal and fetal clinical and laboratory changes associated with elevated s. uric acid, and to determine whether s. uric acid can be used to predict maternal and fetal complications.
INTRODUCTION
A rise of blood uric acid without nitrogen is the most consistent finding of pregnancy induced hypertension and eclampsia. Management of severe pre-eclampsia is like walking on a rope. Slight miss may either lead to maternal or fetal complications or both. While aiming to achieve fetal maturity, many times mother's life is endangered by complications like abruption, renal failure, HELLP (hemolysis, elevated liver enzymes and low-platelets) syndrome and eclampsia. If we analyze the maternal and fetal clinical and laboratory changes associated with elevated uric acid, a laboratory marker may help to standardize the time of termination of pregnancy and optimize fetal and maternal well-being.
MATERIALS AND METHODS
Eighty women of pregnancy induced hypertension (both gestational hypertension and pre-eclampsia) including both mild and severe were randomly selected from women coming to obstetrics and gynecology department of Civil Hospital at Ahmedabad, Gujarat, from January 2011 to March 2012 and were retrospectively studied. Women with complications, like abruption, HELLP, eclampsia, ascites, were included. Variables, such as gestational age, blood pressure, urine albumin, platelet count, S. bilirubin, S. creatinine, S. uric acid, baby weight were considered. From the analysis done below, the study is divided in two groups: Group A consisting of women with S. uric acid > 6 mg/dl while group B consists of women with S. uric acid < 6 mg/dl. Chi-square ( 2 ) test and student t-test were used to compare variables, and tests were considered significant when p-value < 0.05.
RESULTS
S. uric acid level > 6 mg/dl was associated with more proportion of women getting complicated. Analysis has been done after removing outliers from the data. Group A includes 30 women, while group B includes 50 women. Statistically significant elevation of uric acid was found in women of eclampsia. Ten out of 13 women of eclampsia (76%) had elevated s. uric acid. Table 1 shows the distribution of s. uric acid levels among complicated and uncomplicated women. Twenty-four women out of 74 had complications. The mean S. uric acid in complicated women was 6.49 mg/dl compared to 5.62 mg/dl in uncomplicated women. Figures 1 and 2 indicate that S. uric acid level in complicated women ranges from 4 to 11 mg/dl, whereas S. uric acid level in women without complication has lower range of 2 to 9 mg/dl. Table 2 shows proportion of women developing complication in groups A and B. Fourteen out of 30 women (46.6%) with uric acid > 6 mg/dl developed complication compared to 10 out of 50 women (20%) with uric acid < 6 mg/dl, which is statistically significant (p = 0.01). Table 3 and Figure 3 show various complications developing with elevated S. uric acid. Out of 25 complications, six women developed HELLP (24%), two ascites (8%), 13 eclampsia (52%) and four developed abruption (16%). Figure 4 shows the level of S. uric acid in women of HELLP, ascites, eclampsia and abruption. The values in eclampsia range from 5 to 8.5 mg/dl while of HELLP range from 4 to 8 mg/dl. Values from 4.2 to 10 mg/dl were seen in abruption. 
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The mean uric acid of women with complications was 6.49 mg/dl while without complication was 5.62 mg/dl, the difference between the two being statistically significant at p = 0.014 (Table 4 ). The complications seem to develop, when uric acid level exceeds 6 mg/dl. Figure 5 shows the occurrence of preterm delivery in women with uric acid > 6. The mean gestational age at delivery in group A (S. uric acid > 6) was statistically lower than that in group B (S. uric acid < 6) (8.07 vs 8.40; p = 0.057). However, difference in two means was only 0.33 months or 10 days. Table 6 indicates the mean S. creatinine concentration in both the groups. Group A had significantly higher mean S. creatinine concentration compared to group B (1.113 mg/dl vs 0.879 mg/dl; p = 0.05).
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Baby Weight and Uric Acid Level
The average baby weight in group A (U-acid level > 5.5) was significantly lower than the average baby weight in group B (U-acid level < 5.5), (1.726 kg compared to 2.069 kg; p = 0.01), which indicates that women with S. uric acid level > 5.5 tend to deliver babies of lower birth weight (Table 8 and Fig. 6 ). Table 7 shows the comparison of birth weight of women with different levels of uric acid. Considering less than 2 kg as low birth weight, levels of greater than 5.5 are associated with significant low birth weight.
DISCUSSION
Pre-eclampsia leads to altered renal excretion of uric acid leading to increased levels of serum uric acid. Increasing levels of uric acid are associated with increasing number of maternal complications. Severe pre-eclampsia leads to maternal complications, such as abruption, eclampsia, HELLP, renal failure and fetal complications, such as low birth weight including preterm and small for gestational age and increased perinatal mortality. Sibai and Barton 1 reviewed seven studies on expectant management of severe pre-eclampsia from 26 to 34 weeks published since 2000 including more than 1200 women. Average time gained ranged from 5 to 10 days with maternal morbidity like abruption (8-20%), HELLP (5-27%), pulmonary edema (4%), ARF (2-3%) and eclampsia (2%). The perinatal outcomes ranged from 22 to 94% SGA babies and mortality up to 18%. According to Wakwe VC, 2 for women with pre-eclampsia who developed convulsions, there invariably was a further rise in the plasma uric acid levels. Monitoring of plasma uric acid level in those with pre-eclampsia will help to predict those that will develop eclampsia. To avoid these complications and optimize neonatal outcomes, pregnancy should be terminated under glucocorticoid coverage with a uric acid of 6 and above.
